New targeted drug safety check for advanced breast cancer in india
NCT ID NCT06429761
First seen Oct 31, 2025
Summary
This phase 4 study is testing the safety of trastuzumab deruxtecan, a targeted antibody-drug combination, in 100 Indian adults with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. Participants have already received at least one prior anti-HER2 treatment. They will receive the drug by IV every 3 weeks for up to 9 cycles. The main goal is to track side effects and ensure the drug is safe in this specific population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBangalore, 560017, India
-
Research Site
RECRUITINGDelhi, 110029, India
-
Research Site
RECRUITINGKochi, 682041, India
-
Research Site
RECRUITINGMumbai, 400012, India
-
Research Site
RECRUITINGPune, 411028, India
-
Research Site
RECRUITINGVaranasi, 221005, India
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (a targeted antibody-drug combination)
What this could lead to
If successful, this could confirm that trastuzumab deruxtecan is safe for Indian patients with advanced HER2+ breast cancer, supporting its use as a standard treatment option.
What could go wrong
This is a single-arm, open-label study focused on safety, not efficacy. Side effects like nausea, fatigue, or lung inflammation may occur, and results may not apply to other populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.